The increasing incidences of mortality rates on account of liver cancer across the world is boosting the global Hepatocellular carcinoma treatment market, says Fortune business Insights in their new report. The report is titled, “Hepatocellular Carcinoma (HCC) Treatment Market Size, Share and Global Trend by Treatment (Interventional Radiology, Chemotherapy, Radiation Therapy, Surgery, Targeted Therapy, Immunotherapy), By End User (Hospitals, Clinics, Cancer Rehabilitation Centers, Ambulatory Surgery Centers), and Geography Forecast till 2026.”
According to this report, the market may be expected to be dominated by the nanoKnife surgery with respect to the treatment segment. It is a minimally invasive option for patients with liver cancer having an inoperable tumor, which is less than three centimeters. This segment is anticipated to gain major revenues in the forecast duration as compared to other treatment methods such as radiofrequency ablation, intra-arterial chemotherapy, chemoembolization, and others.
Rising Incidences of Liver Tumors Creating Lucrative Growth Opportunities for Market
The rising incidences of chronic diseases of the liver are a major factor propelling growth of the global Hepatocellular carcinoma treatment market. Also known by the name, malignant hepatoma, it is the major cause of liver malfunction leading to cirrhosis. These tumors multiply with local expansion, that spreads into the intrahepatic region and then distant metastases. The rising number of cases of these tumors occurring in a majority of people is adding boost to the global Hepatocellular carcinoma market during the forecast period.
On the flipside, the market may face challenges in terms of risks associated with post surgical treatments. These include Hepatitis B virus (HBV) infection, metabolic syndrome, alcoholic cirrhosis, Hepatitis C virus (HCV) infection, chronic liver injury, and biliary cirrhosis. Again, the side effects of chemotherapy such as hair fall may also restrict the growth of the Hepatocellular carcinoma market in the long run. Another major challenge for the growth of the market is the high cost of treatment and unavailability of reimbursement policies in developing nations.
Nevertheless, the increasing incidences of hepatic cancer namely intrahepatic bile duct cancer especially in developed nations of the U.S. are a major driver for the market to grow remarkably in future.
Browse Complete Report Details at https://www.fortunebusinessinsights.com/industry-reports/hepatocellular-carcinoma-hcc-treatment-market-100326
Europe and Asia Pacific to Show Promising Growth Owing to Rising Number of Liver Cancer Cases
Fortune Business Insights foresees the global Hepatocellular carcinoma treatment market to be dominated by North America. This is because of the rising prevalence of the chronic liver diseases, coupled with the increasing number of liver diseases in the region. A survey conducted in 2017 by the Health Science Department, University of California, Los Angeles stated that 70% of all liver cancer cases is registered in the U.S. with an estimated 40,000 people diagnosed and 28,000 deaths reported due to Hepatocellular carcinoma.
Additionally, the market in Asia Pacific and Europe is also expected to show remarkable growth during the forecast duration. This is attributable to the rising number of research and development projects conducted in the regions for discovering better therapeutics. The World Health Organization conducted a survey in 2017 in the regions and states that an estimated 63,000 people were diagnosed with liver cancer in Europe and about 36,000 people were diagnosed with liver cancer in Japan. Such high occurrence of liver cancer in the regions is expected to open great opportunities of growth for the Hepatocellular carcinoma treatment market in the respective regions.
Some of the companies operating in the global Hepatocellular carcinoma (HCC) Treatment Market are Novartis AG, AbbVie Inc., Pfizer Inc., CELGENE CORPORATION, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Amgen Inc., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Bayer AG, Johnson & Johnson Services, Inc., and others.
View Related Report at
Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies interspersed with relevant data.
At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.